Background: Atopic dermatitis (AD) and allergic contact dermatitis (ACD) are both forms of eczema and are common inflammatory skin diseases with a central role of T cell-derived IL-22 in their pathogenesis. Although prostaglandin (PG) E 2 is known to promote inflammation, little is known about its role in processes related to AD and ACD development, including IL-22 upregulation. Objectives: We sought to investigate whether PGE 2 has a role in IL-22 induction and development of ACD, which has increased prevalence in patients with AD. Methods: T-cell cultures and in vivo sensitization of mice with haptens were used to assess the role of PGE 2 in IL-22 production. The involvement of PGE 2 receptors and their downstream signals was also examined. The effects of PGE 2 were evaluated by using the oxazolone-induced ACD mouse model. The relationship of PGE 2 and IL-22 signaling pathways in skin inflammation were also investigated by using genomic profiling in human lesional AD skin. Results: PGE 2 induces IL-22 from T cells through its receptors, E prostanoid receptor (EP) 2 and EP4, and involves cyclic AMP signaling. Selective deletion of EP4 in T cells prevents hapten-
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ACD: Allergic contact dermatitis AD: Atopic dermatitis AHR: Aryl hydrocarbon receptor cAMP: Cyclic AMP db-cAMP: Dibutyryl cAMP DC: Dendritic cell EP: E prostanoid receptor EtOH: Ethyl alcohol Gapdh: Glyceraldehyde-3-phosphate dehydrogenase ILC3: Group 3 innate lymphoid cell LN: Lymph node PG: Prostaglandin PKA: Protein kinase A eczematous skin include epidermal hyperplasia and spongiosis and infiltration of immune cells (eg, T cells, dendritic cells [DCs] , and eosinophils) in the dermis. 1, 3, 4 Barrier dysfunction is also recognized as important for AD development. [5] [6] [7] In response to antigen and hapten sensitization, keratinocytes are activated to produce proinflammatory cytokines. Concurrently, skin-resident innate immune cells, such as DCs, capture antigens and migrate to secondary lymphocytes, where they present antigens to T lymphocytes for their activation and differentiation into effector T cells, resulting in ACD initiation when the antigen or hapten is repeatedly applied to the skin. 3 Both T H 1 and T H 2 cells, which are characterized by production of IFN-g or IL-4/IL-13, respectively, have been thought to contribute to ACD pathogenesis, depending on the antigens. 8 For example, although the majority of haptens (eg, 1-fluoro-2,4-dinitrobenzene) induce a T H 1-dominant response, others, like fluorescein isothiocyanate, induce T H 2-dominant responses. 9 Although single-hapten elicitation induces delayed-type hypersensitivity, as a mouse model of human contact dermatitis, 10 repeated hapten challenge results in a chronic late-phase and immediate-type hypersensitivity response, which is clinically relevant to the acute phase of AD in human subjetcs. [11] [12] [13] However, recent studies have shown that IL-17 and IL-22, which are produced by T H 17 and other activated T cells, including T H 22 cells, are also critical in mediating the initiation and progression of ACD and AD. [14] [15] [16] [17] [18] [19] [20] In patients with ACD to nickel, there were upregulated levels of IL-22 in both serum and inflamed skin. 19, 20 Furthermore, IL-22 levels in serum from patients with AD are greater than those in healthy subjects, 21, 22 and IL-22 1 T cells infiltrate into lesional AD skin, 23 where IL-22 induces epidermal hyperplasia and inhibits epidermal differentiation. 24, 25 Importantly, a neutralizing anti-IL-22 antibody (NCT01941537) or targeting components of the IL-23/T H 17 pathway are currently being tested in clinical trials. 4, 26 To refine future therapies, there is a need to better understand the mechanisms that drive IL-22 production in response to cutaneous antigen stimulation.
Prostanoids, including prostaglandin (PG) D 2 , PGE 2 , PGF 2a , PGI 2 , and thromboxane A 2 , are bioactive lipid mediators that are generated from arachidonic acid by COXs and then respective PG synthases. PGs have various roles in patients with inflammatory skin diseases through regulating functions of immune cells, including T H 1/T H 17 T cells, regulatory T cells, mast cells, and DCs. 27 PGE 2 is synthesized by microsomal PGE synthases (mPGES1 and mPGES2) and has essential roles in modulating various inflammatory responses by binding to E prostanoid receptors 1 to 4 (EP1-4) on cell surfaces. Many cutaneous cells, including keratinocytes, mast cells, eosinophils, fibroblasts, DCs, and lymphocytes, express PGs and PG receptors. 28 Increased PGE 2 expression in biologically active amounts has been reported in both lesional and nonlesional skin from patients with AD. 29 Blockade of PG production by a COX2 inhibitor was reported to enhance eosinophil infiltration and increase IL-4 expression in lesions of an ovalbumin-sensitized mouse model. 30 In contrast, PGE 2 was also suggested to induce AD by favoring a T H 2 immune milieu and directly enhancing B-cell production of IgE. 31, 32 Furthermore, we and others have recently reported that PGE 2 , through EP2 and EP4 receptors, augmented IL-17 and IL-22 production, and blockade of PGE 2 signaling during T-cell differentiation limited acute contact hypersensitivity. [33] [34] [35] These findings suggest that PGE 2 can have both suppressive and provocative roles in the development of ACD and AD. 28 However, it is unclear how PGE 2 regulates IL-22 production and chronic atopic skin inflammation.
Here we report that PGE 2 promotes IL-22 production from T H 17 and T H 22 T cells through its receptors EP2 and EP4. This effect is mediated by cyclic AMP (cAMP)-protein kinase A (PKA) signaling and induction of aryl hydrocarbon receptor (AHR), a transcription factor critical for both adaptive and innate IL-22 expression. 36 T cell-specific EP4 deficiency diminishes hapten-induced IL-22-expressing T cells in skin-draining lymph nodes (LNs). Accordingly, inhibition of PGE 2 production limits skin inflammation in an animal model for ACD induced by repeated oxazolone challenges in mice. Furthermore, genes related to PGE 2 signaling are overexpressed in human atopic lesional skin, and their expression correlates positively with expression of IL-22 pathway genes. This relationship between expression of PGE 2 and IL-22-related genes is no longer evident after successful corticosteroid or UVB treatments. These findings suggest that PGE 2 facilitates ACD through promoting adaptive IL-22 signaling.
METHODS Mice
Wild-type C57BL/6 mice were purchased from Harlan UK (Bicester, United Kingdom). Lck-Cre mice were crossed to lox-flanked Ptger4 (EP4-floxed) mice 37 to generate mice with selective EP4 deficiency in T cells (EP4cKO), as previously reported. 34, 35 All mice were bred and maintained under specific pathogen-free conditions in accredited animal facilities in the University of Edinburgh and Kyoto University. Mice were aged greater than 7 weeks at the beginning of use and sex matched. All experiments were conducted in accordance with the UK Scientific Procedures Act of 1986 and had local institutional ethical approval.
Reagents
Antibodies to mouse CD3 (clone 145-2C11), CD28 (clone 37.51), CD45 (clone 30-F11), CD4 (clone L3T4), CD8 (clone 53-6.7), IL-17A (clone eBio17B7), and IL-22 (clone IL22J0P) were from eBioscience (San Diego, Calif) or BioLegend (San Diego, Calif). Mouse CD4 microbeads were from Miltenyi Biotec (Bergisch Gladbach, Germany). Recombinant human TGFb1 and recombinant mouse IL-6 and IL-23 were purchased from BioLegend. PGE 2 , 17-phenyl trinor PGE 2 (EP1/3 agonist), butaprost (EP2 agonist), CAY10598 or L-902,688 (EP4 agonist), PF-04418948 (EP2 antagonist), and L-161,982 (EP4 antagonist) were from Cayman Chemicals (Ann Arbor, Mich). Dibutyryl cAMP (db-cAMP), PKA inhibitor 14-22, CH-223191, oxazolone, indomethacin, phorbol 12-myristate 13-acetate, and ionomycin were from Sigma (St Louis, Mo) or Calbiochem (Nottingham, United Kingdom).
Oxazolone-induced ACD model
The oxazolone-induced mouse ACD model was induced, as previously reported. 11 Briefly, mice were sensitized with 3% oxazolone in ethyl alcohol (EtOH) on shaved abdominal skin and after 5 days were repeatedly challenged with 0.6% oxazolone in EtOH on one ear once every 2 days for a total of 5 challenges. The opposing ear was challenged with vehicle (pure EtOH) to serve as a control. Mice were culled at 6 hours after the last challenge, and the ears and ear-draining LNs were collected for further analysis. Ear samples were fixed with 10% neutral-buffered formalin solution (Sigma) and embedded in paraffin wax, and 5-mm sections were used for staining with hematoxylin and eosin. In some experiments EP4cKO or control mice were sensitized with 0.5% dinitrofluorobenzene, and 5 days later, skin-draining LNs were collected for further analysis.
T-cell isolation and culture

Mouse CD4
1 T cells were isolated from spleens by using autoMACS (Mil- 
Surface and intracellular staining
For surface staining, cells were stained on ice for 30 minutes with anti-CD45, anti-CD3e, anti-CD4, and anti-CD8 antibodies. For intracellular staining of IL-22, cells were stimulated with phorbol 12-myristate 13-acetate and ionomycin for 4 to 5 hours in the presence of GolgiPlug (BD Biosciences, San Jose, Calif). Cells were then harvested and fixed with BD Cytofix/Cytoperm Fixation Buffer (BD Biosciences) for 30 minutes and then stained with anti-human/mouse IL-22 (clone IL22JOP, eBioscience) or antihuman IL-22 in BD Perm/Wash Buffer for 1 hour. Flow cytometry was performed on a BD LSRFortessa (BD Biosciences) and analyzed by using FlowJo software (TreeStar, Ashland, Ore).
Real-time PCR
RNA purification from T cells was performed with the RNeasy Mini Kit (Qiagen, Hilden, Germany). cDNA was obtained by using reverse transcription with High-capacity cDNA Reverse Transcription Kits (Applied Biosystems, Foster City, Calif). Samples were analyzed by using real-time PCR with SYBR Premix Ex Taq II (Tli RNase H Plus) kit (Takara Bio, Mountain View, Calif) or GoTaq qPCR Master Mix (Promega, Madison, Wis) on the Applied Biosystems 7900HT Fast machine. The following primers were used: glyceraldehyde-3-phosphate dehydrogenase (Gapdh) forward, 59-TGAACGGGAAGCTCACTGG-39;
Gapdh reverse, 59-TCCACC ACCCTGTTGCTGTA-39; Il22 forward, 59-CATGCAGGAGGTGGT ACCTT-39; Il22 reverse, 59-CAGACGCAAGCATTTCTCAG-39; Ahr forward, 59-TGCACAAGGAGTGGACGA-39; and Ahr reverse, 59-AGG AAGCTGGTCTGGGGTAT-39. Expression was normalized to mouse Gapdh and presented as relative expression to control group by using the 2 2DDCt method.
Gene expression of human skin biopsy specimens from microarray data sets
Microarray gene expression data of human skin biopsy specimens were retrieved from Gene Expression Omnibus data sets (GSE16161, GSE32924, GSE36842, GSE32473, and GSE27887). [38] [39] [40] [41] [42] Patients' information and skin sample have been described previously. [38] [39] [40] 42 In brief, skin biopsy specimens were collected from patients with moderate-to-severe AD (SCORAD score, 20-97) and healthy volunteers under institutional review board-approved protocols (written consent obtained). Patients (age, 16-81 years; mean age, 40 years [from 3 cohorts]) with an acute exacerbation of chronic AD and without any therapy for more than 4 weeks were included. Biopsy specimens were obtained from acute lesional skin that was actively involved and erythematous lesions with AD and were frozen in liquid nitrogen for RNA extraction. [38] [39] [40] 42 Gene expression levels were transformed to z-score values to standardize data across a wide range of experiments and to allow for the comparison of microarray data independent of the original hybridization intensities. 43 P values were calculated by using the nonparametric WilcoxonMann-Whitney test, paired nonparametric tests with post hoc Dunn multiple comparisons, or paired 2-way ANOVA test with the post hoc Bonferroni multiple comparisons test. Correlations between expression levels of 2 genes were calculated by using the nonparametric Spearman correlation test.
Statistical analyses
All data were expressed as means 6 SEMs or scatter dot plots in which each dot represents 1 mouse, 1 patient with AD, or 1 healthy subject. Statistical significance between 2 groups was examined by using the Student t test or Mann-Whitney test, whereas 1-way and 2-way ANOVAwith the post hoc Bonferroni multiple comparisons test were used to evaluate multiple groups, unless otherwise indicated in figure legends. Statistical analyses were performed with Prism 6 software (GraphPad Software, La Jolla, Calif), and a P value of less than .05 was considered statistically significant.
RESULTS
PGE 2 promotes IL-22 production in vitro through its receptors EP2 and EP4
Recently, we reported that PGE 2 promotes IL-22 production from group 3 innate lymphoid cells (ILC3s). 35 Thus we evaluated whether PGE 2 also promoted IL-22 production from T cells. To address this question, we isolated CD4 1 T cells from mouse spleens activated with anti-CD3 and anti-CD28 antibodies and cocultured with various cytokines. Addition of exogenous PGE 2 enhanced Il22 gene expression with IL-6 or IL-23 alone, IL-6 plus IL-23 (T H 22-priming condition), or IL-6 plus IL-23 plus TGF-b (T H 17-priming condition; Fig 1, A) . IL-22 protein production in supernatants of primary cell cultures was also increased by PGE 2 in the presence of IL-23 or IL-23 plus IL-6 (Fig 1, B) . It is important to note that these data are in agreement with previous findings 44 that TGF-b inhibits IL-22 production, even in the presence of PGE 2 (Fig 1, A and B) . Moreover, when the same numbers of PGE 2 -stimulated or control T cells were washed and then restimulated with T-cell receptors (ie, anti-CD3 and anti-CD28), PGE 2 -stimulated T cells produced more IL-22 than control T cells, even in the presence of TGF-b (Fig 1, C) , suggesting that PGE 2 -treated cells have higher capability to produce IL-22 at the single-cell level.
To define which PGE 2 receptor mediates IL-22 production, we cultured T cells under T H 22-priming conditions and selectively activated EP2 and EP4. Both EP2 and EP4 agonists individually mimicked augmentation of IL-22 production (Fig 1, D) . To further confirm the roles of PGE 2 -EP2/EP4 signaling in inducing IL-22 production of T cells, we also cultured differentiated T H 17 T cells and found that PGE 2 still promotes IL-23-driven IL-22 gene and protein expression (Fig 1, E and F) . Moreover, enhancement of IL-22 production by EP2 or EP4 agonists was prevented by cotreatment of antagonists against EP2 or EP4, respectively (Fig 1, F) ; increased IL-22 production by PGE 2 was also diminished by coadministration of EP2 and EP4 antagonists (Fig 1, F) . In addition, PGE 2 also increased IL-22 production in T H 17 cells in the absence of other cytokines (Fig 1, E and  F) , suggesting a potentially direct action of PGE 2 to promote Il22 gene expression. These data indicate the involvement of EP2 and EP4 in PGE 2 facilitation of IL-22 production from T cells in vitro.
cAMP promotes IL-22 production from T cells through the transcription factor AHR Because both EP2 and EP4 receptors activate the cAMP-PKA pathway in T cells, 33 we next examined whether cAMP mediates PGE 2 facilitation of adaptive IL-22 production. Like PGE 2 , db-cAMP promoted IL-22 production in a concentration-dependent manner in either the presence or absence of IL-23 (Fig 2, A) , confirming a direct action of cAMP on IL-22 induction. The increased IL-22 production by cAMP was prevented by PKA inhibitor 14-22 in a concentration-dependent manner (Fig 2, B) . cAMP also upregulated Il22 gene expression in IL-23-stimulated T cells, which was prevented by cycloheximide, an inhibitor for eukaryote protein synthesis (Fig 2, C and D) , suggesting that the PGE 2 -cAMP pathway promoted adaptive IL-22 production through synthesis of a new protein or new proteins.
The transcription factor AHR has been reported to regulate IL-22 production in both T cells and ILC3s. 36 Thus we investigated whether AHR contributes to the PGE 2 -cAMP signaling-dependent increase in adaptive IL-22 production. We first checked that both PGE 2 and cAMP upregulated Ahr gene expression in T cells independently of cytokine stimuli (Fig 2, E and F) . Importantly, the small-molecule AHR inhibitor CH-223191 effectively suppressed cAMP-dependent IL22 gene expression and protein production from T cells (Fig 2, G and H) , although it had no effect on Ahr expression itself (Fig 2, F) . These results suggest that PGE 2 -cAMP signaling promotes IL-22 production from T cells through induction of AHR. antagonist L-161,982 were used at 10 mmol/L. All experiments were performed in duplicates or triplicates and repeated 2 to 3 times independently. *P < .05, **P < .01, ***P < .001, and ****P < .0001.
PGE 2 -EP4 signaling promotes adaptive IL-22 production in vivo
To investigate whether PGE 2 promotes adaptive IL-22 production in vivo, we topically sensitized the abdominal skin of control mice and mice with specific EP4 deletion in T cells (EP4cKO mice 34 ) with dinitrofluorobenzene and measured IL-22-producing T-cell numbers in skin-draining LNs 5 days after sensitization using flow cytometry. Both percentages and absolute numbers of IL-22-producing T-cells were reduced markedly in EP4cKO compared with control mice (Fig 3, A and B) . Furthermore, EP4 deficiency reduced Il22 gene expression in skin-draining LN CD4
1 T cells (Fig 3, C) . These data indicate that PGE 2 -EP4 signaling promotes adaptive IL-22 production in vivo.
Endogenous PGE 2 -EP4 signaling in T cells promotes ACD
We next investigated whether PGE 2 has a pathogenic role in development of allergic skin inflammation. To address this question, we used an animal model mimicking human ACD. We sensitized wild-type C57BL/6 mice with 3% oxazolone on abdominal skin, and after 5 days, we repeatedly challenged mice with 0.6% oxazolone every 2 days for a total of 5 challenges. Indomethacin was administrated to mice in drinking water to inhibit endogenous PGE 2 production. Once DCs in the skin capture the antigen oxazolone, they migrate to skin-draining LNs and present antigen to T cells for their activation. Because the migration of antigencapturing DCs to skin-draining LNs peaks between 18 and 24 hours requires PGE 2 -EP4 signaling, 45 we only treated mice with indomethacin 24 hours after the oxazolone sensitization (Fig 4, A) . Consistent with previous reports, 11 repeated challenge with oxazolone induced allergic skin inflammation (Fig 4, B and  C) . Ears of oxazolone-challenged, indomethacin-treated mice showed decreased swelling compared with those of vehicletreated mice (Fig 4, B) . Indomethacin had no effect on the thickness of vehicle (EtOH)-challenged ears. Compared with EtOH-challenged ears, the histology of oxazolone-challenged ear skin showed features of eczema, namely parakeratosis, acanthosis, and focal spongiosis, with a dense and diffuse dermal infiltrate containing eosinophils (Fig 4, C) . However, in skin from indomethacin-treated mice, epidermal changes are less pronounced, and dermal infiltrates are markedly reduced (Fig 4,  C) . Furthermore, although repeated oxazolone challenge recruited CD4
1 and CD8 1 T cells to ear-draining LNs (Fig 4, D) , (Fig 2, C) or presence (Fig 2, D) of cycloheximide (CHX; 1 mmol/L) for 3 days. E, Ahr mRNA expression in naive CD4 1 T cells cultured with anti-CD3/CD28 antibodies and indicated cytokines in the absence or presence of PGE 2 for 3 days. F-H, Ahr (Fig 2, F) and Il22 (Fig 2, G) mRNA expression and IL-22 levels (Fig 2, H) in supernatants of T H 17 cells cultured with anti-CD3/CD28 antibodies, IL-23, db-cAMP, and CH-223191 (10 mmol/L) for 3 days. All experiments were performed in duplicates or triplicates and repeated 2 to 3 times independently. *P < .05, **P < .01, ***P < .001, and ****P < .0001. ns, Nonsignificant.
indomethacin treatment reduced both this recruitment and the Tcell capacity to produce IL-22 (Fig 4, E) . To further investigate whether this proinflammatory effect of PGE 2 on oxazoloneinduced ACD development was mediated by EP4 and T cells, we performed this model on EP4cKO and control (EP4 fl/fl ) mice. Oxazolone induced significantly less ear skin inflammation in EP4cKO compared with control mice (Fig 4, F) , suggesting that PGE 2 -EP4 signaling in T cells promotes ACD development. PGE 2 -dependent IL-22 production and signaling in human atopic lesional skin Because ACD and AD potentially share common cellular mechanisms 4 and the repeated hapten challenge-induced animal model is relevant to the acute phase of AD in human subjects, 11 we next investigated whether PGE 2 -dependent adaptive IL-22 production and signaling can be found in human atopic skin. We analyzed mRNA expression of genes related to PGE 2 metabolism (Fig 5, A) and IL-22 signaling pathways in skin biopsy specimens from human patients with lesional AD and healthy subjects. As reported previously, 39 mRNA expression levels for T H 17/T H 22-related genes (IL17A, IL22, IL23R, and AHR), IL-22-induced products (eg, S100A7, S100A8, and S100A9), and skin-homing chemokines (CCR4) were overexpressed in lesional AD compared with normal skin (Fig 5, B) . [38] [39] [40] 43 Strikingly, mRNA expression levels for PGE 2 synthases (PTGS2, PTGES, and PTGES2) were also upregulated in human atopic lesional skin, and in contrast, expression levels for the PGE 2 degrading enzyme HPGD (hydroxyprostaglandin dehydrogenase 15-[NAD]) was downregulated in lesional AD skin (Fig 5, B) . These gene expression data are consistent with previous reports showing increased PGE 2 levels in lesional AD skin. 21 There was a trend that expression of the PTGER4 gene (encoding PGE 2 receptor EP4) was upregulated in lesional AD skin but expression of PTGER2 (encoding PGE 2 receptor EP2) was significantly downregulated in lesional AD skin (Fig 5, B) . Expression of T H 2 cytokines (eg, IL-4, IL-5, and IL-13) was not significantly upregulated in lesional AD skin; however, T H 2 chemokines, such as CCL26, CCL18, CCL22, CCL17, CCL11, and CCL5, were upregulated in lesional AD skin compared with normal skin (Fig 5, B) . Interestingly, expression of IL-22 pathway genes showed strongly positive correlation with those of PTGES in biopsy samples from lesional AD but not normal skin (Fig 5, C) . There were no correlations between PTGES expression and T H 2 cytokine levels (data not shown), but weak correlations between PTGES gene expression and T H 2 chemokine levels in lesional AD skin were observed (Fig 5, D) . These results suggest that PGE 2 signaling is activated and positively correlates with the IL-22 signaling pathway and, probably, the T H 2 pathway in human atopic skin.
Finally, we investigated whether current therapies for AD modulate PGE 2 signaling in human AD. We analyzed changes in expression levels of IL-22 and PGE 2 signaling genes in lesional AD skin before and after treatments, such as betamethasone (a corticosteroid), by reanalyzing a public microarray data set. 41 Compared with baseline levels, treatments with betamethasone reduced IL22 gene expression in atopic lesional skin (Fig 4, A) . Betamethasone also significantly reduced expression of IL-22-related genes, such as AHR, S100A8, and S100A9 (Fig 6, A) . 41 Expression of PGE 2 synthases (eg, PTGES and PTGES2) and the EP4 receptor (PTGER4) was significantly downregulated by betamethasone treatment, whereas EP2 receptor (PTGER2) expression was not changed (Fig 6, A) . This observation is consistent with findings that betamethasone treatment reduces PGE 2 production. 46, 47 Interestingly, expression of PTGES, PTGES2, and PTGER4, but not PTGER2, positively correlated with IL22 expression in atopic biopsy specimens at baseline, whereas expression of HPGD, which mediates PGE 2 degradation, negatively correlated with IL22 expression (Fig 6, B) . Furthermore, we have also reanalyzed gene expression of skin biopsy specimens before and after treatment with UVB from our previous data set. 42 Expression of the PGE 2 synthases PTGS1 and PTGES in lesional AD skin was downregulated after treatment with UVB (Fig 6, C) . 42 Interestingly, although IL22 gene expression was not changed by UVB treatment, most likely because of the small number of samples, changes in expression of IL-22-activated genes (eg, S100A8 and S100A9) positively correlated with changes in expression of PGE 2 synthases (ie, PTGS1, PTGES, and PTGES2) in atopic lesional but not nonlesional biopsy specimens (Fig 6, D, and data not shown) . Together, these data indicate that PGE 2 , most likely through the EP4 receptor, plays a role in IL-22 regulation in human skin.
DISCUSSION
The cytokine IL-22, which is notably produced by T H 22 and T H 17 T cells, is emerging as a key player in AD, 3, 16, 23 leading to a new therapy targeting IL-22 signaling in AD clinical trials (NCT01941537). Genome-wide association studies have identified that gene polymorphisms of the PGE 2 receptor EP4 were associated with T cell-mediated human autoimmune and allergic inflammatory diseases. 48, 49 However, the role of PGE 2 in promoting IL-22 production and development of AD remains to be determined. To address this, ideally, a model that showed the features of AD would be used. However, because no single animal model can fully capture all aspects of the human AD profile 50 and there is acceptance that there are shared common cellular mechanisms between AD and ACD, 3 we used a repeated hapten challenge ACD model to study the role of PGE 2 signaling in IL-22
1 T cells and development of chronic skin inflammation. We also analyzed gene expression in human AD lesional skin before and after common treatments for AD to examine the PGE 2 -IL-22 axis in the relevant human skin disease in both the chronic inflammatory phase and after therapeutic intervention.
We show that PGE 2 markedly stimulates IL-22 production from T cells, which complements our previous findings that PGE 2 promotes innate IL-22 production from ILC3s. 35 It is worth noting that PGE 2 promotes IL-22 production from freshly activated CD4
1 T cells under various conditions, including T H 17-and T H 22-priming conditions. The effect of PGE 2 was mimicked by activation of EP2 and EP4 receptors and was prevented by antagonists against these receptors, confirming the involvement of these 2 receptors in adaptive IL-22 production in vitro. Further studies showed that the cAMP-PKA signaling pathway, which is activated by engagement of EP2 and EP4, mediates PGE 2 enhancement of IL-22 production through induction of the newly expressed AHR. Thus our results uncover a new and targetable molecular mechanism for regulation of adaptive IL-22 by the PGE 2 -cAMP-AHR axis.
The role of PGE 2 in promoting adaptive IL-22 production was also confirmed in vivo. T cell-specific EP4 deficiency led to a large reduction of IL-22
1 T cells in skin-draining LNs in response to hapten sensitization and attenuated repeated oxazolone challenge-induced allergic skin inflammation in the mouse model of ACD, indicating a critical role of endogenous EP4 signaling in T cells for IL-22 expression and function in vivo. This is similar to innate IL-22 expression, which also requires PGE 2 -EP4 signaling, 35 suggesting a shared mechanism for regulating both Indo, Indomethacin. F, Swelling of ears from control and EP4cKO mice (n 5 9-13) sensitized and repeatedly challenged with OXA as in Fig 4, A, but without indomethacin treatment. *P < .05, ***P < .001, and ****P < .0001.
FIG 5.
Overexpression of PGE 2 signaling genes in human lesional AD skin, which positively correlates with expression of IL-22-signaling genes. A, Schematic depicting synthesis and metabolism of PGE 2 mediated by COX2 (encoding by PTGS2), PGE synthases (encoding by PTGES or PTGES2), and 15-PGDH (encoding by HPGD), respectively. The PGE 2 receptor EP4 (encoding by PTGER4) is also shown. B, Heat map of expression profiles of T H 2 cytokine and chemokine genes and genes related to IL-22 and PGE 2 pathways in human lesional AD skin (n 5 38) and normal skin (n 5 32). A color scale bar indicates the z-score transformed values of microarray gene expression data. [38] [39] [40] Ratios of z scores represent changes in gene expression levels between the healthy and AD lesional groups.
43 P values were calculated by using nonparametric WilcoxonMann-Whitney tests. Probes with the largest z-score ratios were chosen when several probes represented single genes. C and D, Correlations of PTGES gene expression versus expression of IL-22 pathway genes (Fig 5, C) or T H 2 chemokines (Fig 5, D) in atopic lesional and normal skin. P values were calculated by using the nonparametric Spearman correlation test.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 1 the adaptive and innate IL-22 responses. Inhibition of endogenous PGE 2 production by a COX inhibitor successfully prevented accumulation of T cells in ear-draining LNs, reduced T-cell production of IL-22, and attenuated allergic skin inflammation induced by repeated oxazolone challenges. Given that PGE 2 also promotes IL-17 production from both mouse and human T H 17 T-cells 33, 51 and that IL-17 might participate in creating the ACD phenotype, [14] [15] [16] [17] [18] [19] [20] IL-17 might also be involved in the PGE 2 -facilitated ACD pathogenesis.
Facilitation of IL-22 production by PGE 2 might contribute to several human inflammatory diseases, such as AD and psoriasis. 52 Indeed, parallel upregulations of IL-22 pathway genes and PGE 2 FIG 6. Steroid and UVB therapies downregulate PGE 2 and IL-22 signaling pathway genes in human atopic lesional skin. A, Expression profiles of genes related to PGE 2 and IL-22 pathways in human lesional AD skin (n 5 10) at baseline (AD Base) or after treatment with betamethasone for 3 weeks. The z-score transformed values of microarray gene expression data 41 were used. P values were calculated by using paired nonparametric tests with the post hoc Dunn multiple comparisons test. B, Correlations of PTGES, PTGES2, HPGD, and PTGER4 gene expression versus that of the IL22 gene in human atopic lesional skin at baseline. P values were calculated by using the nonparametric Spearman correlation test. C, Expression of genes related to PGE 2 and IL-22 signaling in human atopic lesional (AL, n 5 8) and nonlesional (ANL, n 5 7) skin before (PRE) or 12 weeks after (POST) treatment with UVB. The z-score transformed values of microarray gene expression data 42 were used. P values were calculated by using the paired 2-way ANOVA test with the post hoc Bonferroni multiple comparisons. D, Correlations of changes in expression of IL-22-induced genes (S100A8, andS100A9) and PGE 2 synthase genes (PTGS1, PTGES, and PTGES2) before (PRE) and after (POST) UVB therapy in atopic lesional or nonlesional skins. P values were calculated by using the nonparametric Spearman correlation test.
synthases were observed in human atopic lesional skin, whereas levels of the PGE 2 degrading enzyme 15-PGDH (encoded by HPGD) were downregulated in AD skin. This is consistent with previous observations showing increased PGE 2 levels in lesional AD skin. 29 Moreover, our data indicate that IL-22 signaling positively correlated with PGE 2 signaling in atopic lesional skin, and these correlations were absent in both normal and lesional AD skin after successful steroid or UVB treatments. These findings potentially suggest a PGE 2 -dependent IL-22 production and signaling in human atopic skin.
In addition to IL-22 1 T cells, T H 2 cells (especially the cutaneous lymphocyte antigen-positive population with skinhoming capacity) are expanded in patients with severe AD. 53 T H 2 cells suppress major terminal differentiation proteins (ie, filaggrin and loricrin) and predominate in the acute phase of AD through production of cytokines (eg, IL4 and IL13) and chemokines (eg, CCL17, CCL18, and CCL26). 40, 54 Thus the T H 2 response is critical for AD pathogenesis. Inhibition of COX2 has been reported to enhance T H 2 cytokine production and the T H 2 response to ovalbumin-induced epicutaneous sensitization, 30 suggesting a potential inhibitory role of PGs in T H 2 cell-driven allergic inflammation. In human lesional AD skin, however, there was no correlation between the PGE 2 pathway and T H 2 cytokines, and in contrast, there were weak positive correlations between the PGE 2 pathway and T H 2 chemokines, suggesting a possible promoting role of PGE 2 in T H 2 response in patients with AD. This might be because PGE 2 promotes IL-17 and IL-22 production [33] [34] [35] 49 and subsequently IL-17 exacerbates T H 2-type inflammation during the initiation of AD. 11, 55 We acknowledge this report has several limitations. For example, our analysis of gene expression profiles in human skin biopsy specimens were retrieved from public Gene Expression Omnibus data sets, and confirmation of these findings was not performed by using methods with higher sensitivity, such as real-time PCR with fresh biopsy specimens. Moreover, cytokine expression in protein levels in different T-cell subsets were not measured by using flow cytometry in skin of patients and animals. Furthermore, although in mice the oxazolone repeated challenge-induced chronic allergic skin inflammation represents a robust model, additional animal models are required in attempt to fully mimic most pathogenic and physiologic processes during the development of human AD. In addition, because of a limitation of resources, the effects of PGE 2 signaling in T cells, especially the involvement of both EP2 and EP4 in T cells, on initiation and progression of ACD could not be interrogated, such as using mice with T cell-specific deficiency of both EP2 and EP4 receptors. Therefore future prospective studies are required to further understand not only the role of PGE 2 during perpetuation of ACD and AD skin inflammation but also during their onset.
In conclusion, our data ascertain that PGE 2 acts as a potent promoter of both adaptive and innate IL-22 production. We have previously found that PGE 2 signaling promotes DC production of IL-23, a cytokine essential for IL-22 expression, as well as for proliferation and maturation of T H 17 T cells. 33 Taken together, our results highlight the PGE 2 signaling pathway as an important stimulus of T-cell responses and ACD and, possibly, AD development. Thus targeting PGE 2 synthesis or its receptors might represent a possible therapeutic strategy for the treatment of ACD and AD and other inflammatory skin diseases, such as psoriasis, with an active role for IL-22.
